Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO report confirms appropriate FDA action on RU-486

Executive Summary

The Government Accountability Office confirms in an Aug. 7 report that FDA's approval and oversight of Danco Laboratories' Mifeprex (mifepristone), approved in 2000 for termination of early term pregnancy, was consistent with its regulatory approach to other Subpart H restricted drugs. Members of Congress had suggested that FDA approved Mifeprex (also known as RU-486) under Subpart H outside the regulation's original purpose (1"The Pink Sheet," April 30, 2007, p. 30). After reviewing the GAO report, Senate Health, Education, Labor and Pensions Committee Ranking Member Michael Enzi, R-Wyo., said, "While FDA's actions on RU-486 may have been consistent with the agency's actions on other drugs at the time, these actions were not sufficient to protect patient safety. ... This GAO report confirms that we did the right thing in [FDAAA]." Mifeprex is one of 16 drugs retroactively deemed to require Risk Evaluation & Mitigation Strategies, and Danco will have to adhere to the new requirements by September 21 (2"The Pink Sheet," March 31, 2008, p. 7)

You may also be interested in...

REMS Take Effect; FDA Identifies 16 Products With RiskMAPs That Qualify

Manufacturers of approved products whose marketing conditions qualify for a Risk Evaluation and Mitigation Strategy will have to develop a timeline for the assessment of their risk management efforts by September 21

Sen. Coburn Plays It Safe; FDA Will Review Medical Marijuana But Not RU-486

A path to federal legalization of state-sanctioned medical marijuana was approved by the Senate Health, Education, Labor and Pensions Committee as part of the markup of a bill renewing FDA's user fee program

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts